Abbreviated Name

Lung Ref Set A App: Coverley (2011)

Lead Investigator

Coverley, Dawn — University of York

Coordinating Investigator

Zheng, Yingye — Fred Hutchinson Cancer Center

Involved Investigators

• Srivastava, Sudhir — National Cancer Institute
• Coverley, Dawn — University of York
• Zheng, Yingye — Fred Hutchinson Cancer Center

Abstract

No abstract availalbe.

Aims

There are four primary clinical questions to be addressed in the pre-validation study: 1) Whether b-variant Ciz1 as a single plasma biomarker has the potential for adding value to current clinical tests (CT scan and/or PET scan) in the diagnostic evaluation of pulmonary nodules with a goal of reducing invasive tests (PET or tissue biopsy) or futile thoracotomies; 2) Whether b-variant Ciz1 as a single plasma biomarker has the potential for adding value to current tests (CT scan and/or PET scan) in the early diagnosis/detection of lung cancer in high risk individuals, with a goal of reducing invasive tests (PET or tissue biopsy) or futile thoracotomies and more importantly, missed cures; and 3) Whether b-variant Ciz1 as a single plasma biomarker has the potential for adding value to current clinical tests (CT scan, PET scan and biopsies) in the staging of lung cancer; and, 4) Whether b-variant Ciz1 as a single plasma biomarker has the potential for adding value to current clinical tests (e.g., CT scan, PET scan and biopsies) in determining prognosis of lung cancer patients; and, A Secondary clinical question is whether b-variant Ciz1 as part of a panel of biomarkers has the potential for adding value to one or more of the above primary clinical utilities.

Analytic Method

Provide adequate detail concerning how statistical analysis of your data generated from the Reference Set(s) samples will be performed and a justification that the requested References Set(s) is/are large enough to demonstrate the utility of the biomarker. Describe the statistical resources at your disposal. If you require statistical support, the EDRN/SPOREs can assist you with this.

Comments

No Data Received at DMCC. Assay didn't work well on the samples provided.

Outcome

A variant of the nuclear matrix factor Ciz1 is prevalent in lung cancer cell lines and tumours, but not in adjacent lung tissue, giving rise to a protein that is stable enough to be detected in just one ul of plasma. This project evaluates the potential of variant Ciz1 as an early detection tool for lung cancer, using variant-selective antibodies.

Publications

• No publications available at this time for this protocol.

Biomarkers

• CIZ1

Data Collections

• No data collections available at this time for this protocol.

Start Date

Sep 28 2011

Estimated Finish Date

Sep 27 2012

Finish Date

Mar 27 2012

Protocol ID

341

Protocol Type

Reference Set

Fields of Research

• Proteomics

Collaborative Group

Lung and Upper Aerodigestive Cancers Research Group

Cancer Types

• Malignant neoplasm of bronchus and lung

Phased Status

1